glp-1 receptor agonists fatigue side effects Your guide to Clinical Recommendations to Manage Gastrointestinal

GLP-1 and its synthetic analogs have emerged as significant therapeutic agents for the management of metabolic disorders, merging glycemic control with weight loss through innovative structural and delivery breakthroughs

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects

The list of conditions for which GLP-1 drugs provides benefit independent of weight loss keeps growing

They stimulate insulin secretion and inhibit glucagon secretion by elevating e...